An orally available selective inhibitor of ALK (IC50 1 9 nM) that also inhibits F1174L R1275Q and L1196M mutants of ALK (IC50s 1 0 3 5 and 1 6 nM respectively) inhibits the growth of tumors in mouse xenograft models of nonsmall cell lung cancer and anaplastic large-cell lymphoma